Why These 24 Stocks Are Skyrocketing

Page 4 of 23

20. Cidara Therapeutics, Inc. (NASDAQ:CDTX)

Q4 Returns as of December 31, 2024: 150%

Shares of CDTX rose to $26.9 on December 31, marking a 150% increase from the $10.75 close on September 30, 2024, emphasizing investors’ optimism on the company’s further growth potential in the therapeutics industry.

Analysts expect CDTX to reach $33, implying an upside of 24% from current levels. According to analysts, the company has grown its revenue by 45% year-over-year and by 19% over the past five years.

Earlier, analyst firm WBB Securities rated the stock as a strong buy and raised its price target for CDTX from $40 to $45. Similarly, analyst firm RBC Capital initiated an outperform rating following a price target of $34.

Page 4 of 23